Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
43
Participants
Timeline
Start Date
January 31, 2007
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2012
Conditions
Lung NeoplasmsErlotinibNeoadjuvant Therapy
Interventions
DRUG
Erlotinib
Erlotinib 150mg per day for 8 weeks
Trial Locations (1)
Unknown
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT01130753 - Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter